From the pioneering 68Ga-PSMA-11 to the therapeutic breakthroughs with 177Lu-PSMA-617 and other emerging compounds, these radiolabeled PSMA-targeting agents have significantly enhanced our ability to detect and manage prostate cancer. Here, FOLH1 is linked to prostate carcinoma.